VIR-1388 is under clinical development by Vir Biotechnology and currently in Phase I for Human Immunodeficiency Virus (HIV) Infections (AIDS). According to GlobalData, Phase I drugs for Human Immunodeficiency Virus (HIV) Infections (AIDS) have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how VIR-1388’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VIR-1388 is under development for the prevention of human immunodeficiency virus (HIV) infections (AIDS). It is HIV T cell vaccine based on human cytomegalovirus vector (HCMV) and is administered through subcutaneous route. It is being developed based on T-cell based viral vector platform.
Vir Biotechnology overview
Vir Biotechnology (Vir) is a biotechnology company which carries out the development of therapeutic products to prevent and treat serious infectious diseases. It develops treatments for viral and bacterial diseases and induce protective and therapeutic immune responses. The company includes in multi-program, multi-platform approach. Vir focuses on chronic infectious diseases including hepatitis B, tuberculosis, HIV; respiratory diseases, including influenza, respiratory syncytial virus (RSV) and metapneumovirus (MPV), healthcare-acquired infections. It has operations in Portland, Oregon, Boston, Massachusetts, Bellinzona, Switzerland. Vir is headquartered in San Francisco, California, the US.
For a complete picture of VIR-1388’s drug-specific PTSR and LoA scores, buy the report here.